9 citations
,
April 2023 in “Experimental Dermatology” This study found that adding allergen immunotherapy to conventional treatment may reduce relapse-related hair loss in house dust mite-allergic alopecia areata patients over a 3-year period.
1 citations
,
April 2023 in “Frontiers in Immunology” This review explored recent research on the immune mechanisms and potential therapeutic targets for alopecia areata, highlighting the roles of immune-related cells, autocrine and paracrine signaling, as well as factors like adipose-derived stem cells and gut microbiota in disease pathogenesis.
40 citations
,
August 2022 in “Frontiers in immunology” This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.
37 citations
,
December 2021 in “Cells” This study found that dysregulation of systemic Th1, Th2, and Th17 cytokines is associated with alopecia areata, with specific cytokines linked to disease activity and treatment response.
290 citations
,
August 2021 in “Clinical Reviews in Allergy & Immunology” JAK inhibitors show promise for treating alopecia areata, but more research is needed.
56 citations
,
January 2021 in “Clinical and Experimental Medicine” This review highlights the challenges in treating alopecia areata, noting that current therapies often lead to relapse and have uncertain long-term effectiveness; it also points to potential future treatments such as JAK-STAT inhibitors and PRP.
134 citations
,
July 2020 in “Experimental dermatology” This review discusses immune privilege in anagen hair follicles and its collapse in alopecia areata, emphasizing the importance of restoring this function for effective management and disease relapse prevention.
55 citations
,
October 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” This review discusses emerging research areas in alopecia areata pathobiology, highlighting the potential roles of unconventional immune cells and the need for more targeted therapeutic strategies, but reports no new experimental results.
136 citations
,
May 2019 in “Cells” This review discusses the advancements in intraoperative stem cell therapies and highlights their potential to improve hair regrowth, but it reports no new clinical results.
15 citations
,
April 2019 in “Journal of Cellular Biochemistry” This study identified specific miRNAs that are potentially linked to severe active alopecia areata, suggesting they could be targets for future treatment development.
140 citations
,
November 2018 in “Pharmacology & Therapeutics” This review explores the potential of small molecules to activate the Wnt/β-catenin signaling pathway in treating diseases and reports no new experimental findings.
95 citations
,
November 2018 in “Australasian journal of dermatology” This consensus statement outlines a treatment algorithm for alopecia areata, discussing when to consider systemic treatment and how to assess outcomes, without providing new clinical results.
27 citations
,
April 2018 in “Journal of autoimmunity” In this study, iNKT10 cells were found to play a significant role in preventing and treating alopecia areata in a humanized mouse model, suggesting these cells could have potential in managing related autoimmune disorders.
130 citations
,
February 2018 in “Journal of Investigative Dermatology” This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.
222 citations
,
September 2016 in “JCI insight” This research overview highlights that although JAK inhibitors show promise as potential treatments for alopecia areata based on recent insights into the disease mechanism, their efficacy has not yet been thoroughly evaluated in a systematic manner.
196 citations
,
September 2016 in “JCI insight” This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.
68 citations
,
November 2015 in “The Journal of Allergy and Clinical Immunology” In this study, three patients with extensive alopecia areata showed varying degrees of hair regrowth after 20 weeks of treatment with ustekinumab, a cytokine-targeting therapy.
176 citations
,
August 2015 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” This study identified a distinct cytokine activation signature in alopecia areata, involving TH2, TH1, IL-23, and IL-9/TH9 pathways, suggesting potential targeting strategies similar to those in psoriasis and atopic dermatitis.
701 citations
,
August 2014 in “Nature medicine” This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.
29 citations
,
March 2014 in “PloS one” In this study, Astragaloside IV was found to inhibit apoptosis-related pathways in hair follicles of mice, suggesting it may serve as an alternative therapy for hair loss.
